Cybin Inc. reported its unaudited financial results for the first fiscal quarter ended June 30, 2025, with cash and cash equivalents totaling US$118.7 million. Effective April 1, 2025, the company changed its presentation currency from Canadian dollars to United States dollars to better reflect operations and improve comparability.
The company announced receiving European CTA approval and UK MHRA approval for EMBRACE, the second pivotal study evaluating CYB003 for Major Depressive Disorder (MDD). EMBRACE is set to enroll 330 participants at approximately 60 clinical sites across the U.S., UK, Europe, and Australia, significantly expanding the multinational Phase 3 PARADIGM program.
Cybin also provided an update on its CYB004 program, stating that completion of patient enrollment in the Phase 2 study for Generalized Anxiety Disorder (GAD) is expected in August 2025. This milestone moves CYB004 closer to a data readout and potential further development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.